Metagenomi net loss widens 38.05% to $27.48 million in Q2 FY26 - MGX News | RalliesMetagenomi net loss widens 38.05% to $27.48 million in Q2 FY26
M
MGX• Pipeline update
- MGX-001 hemophilia A IND-enabling work is expected to finish by end-Q3 2026; IND filing targeted for Q4 2026 with trials planned in 2027.
Q2 FY26 results
- Metagenomi Therapeutics posted a net loss of $27.48 million, or $0.73 per share, for Q2 2026.
- Collaboration revenue turned negative to a loss of $257,000, from revenue in the year-earlier quarter.
- Operating loss widened to $28.77 million as operating expenses eased to $28.52 million, helped by lower G&A spending.
Cash position and runway
- Cash, cash equivalents, and available-for-sale marketable securities fell to $120.7 million at June 30, with runway projected through Q4 2027.
WHF
•
